Journal of Biological Chemistry · 2004 · 83 citations · 23 references
Life SciencesCell BiologyMolecular BiologyApoptosisBiomolecular ModelingMolecular Cell BiologyApoptosis ResistanceBcl-2 Family ProteinsProtein-protein Interaction ModelingAnti-apoptotic AgentsAnti-apoptotic ProteinsAnti-apoptotic RegulatorsBcl-xl FunctionPro-apoptotic ProteinsRegulation By Bcl-2 Family Proteins
Cells expressing high levels of the BCL-XL anti-apoptotic protein are preferentially killed by the mitochondrial inhibitor antimycin A (AA). Computational modeling predicts a binding site for AA in the extended hydrophobic groove on BCL-XL, previously identified as an interface for dimerization to BAX and related proapoptotic proteins. Here, we identify BCL-XL hydrophobic groove mutants with normal cellular anti-apoptotic function but suppressed sensitivity to AA. The LD50 of AA for cells expressing BCL-XL mutants directly correlates with the measured in vitro dissociation constants for AA binding. These results indicate that BCL-XL is a principal target mediating AA cytotoxicity. Cells expressing high levels of the BCL-XL anti-apoptotic protein are preferentially killed by the mitochondrial inhibitor antimycin A (AA). Computational modeling predicts a binding site for AA in the extended hydrophobic groove on BCL-XL, previously identified as an interface for dimerization to BAX and related proapoptotic proteins. Here, we identify BCL-XL hydrophobic groove mutants with normal cellular anti-apoptotic function but suppressed sensitivity to AA. The LD50 of AA for cells expressing BCL-XL mutants directly correlates with the measured in vitro dissociation constants for AA binding. These results indicate that BCL-XL is a principal target mediating AA cytotoxicity. The BCL-2 family proteins are key positive and negative regulators of apoptosis. Biochemical and subcellular fractionation studies localize the anti-apoptotic members, such as BCL-2 and BCL-XL, at outer mitochondrial membranes (OMM) 1The abbreviations used are: OMM, outer mitochondrial membrane; AA, antimycin A; 2-OMeAA, 2-methoxy antimycin A; BH, Bcl-2 homology; STS, staurosporine; RMSD, root mean square difference; WT, wild-type; Me2SO, dimethylsulfoxide; FITC, fluorescein isothiocyanate. and, to a lesser extent, at endoplasmic reticulum and nuclear membranes. Pro-apoptotic factors either reside at the OMM or as soluble cytosolic proteins, as with BAX, BID, and BAD. Following an apoptotic signal, these factors are translocated to mitochondria. BCL-2 and BCL-XL cancel out the activity of pro-apoptotic members at the OMM, at least partly through direct interactions (1.Minn A.J. Kettlun C.S. Liang H. Kelekar A. Vander H.M. Chang B.S. Fesik S.W. Fill M. Thompson C.B. EMBO J. 1999; 18: 632-643Crossref PubMed Scopus (184) Google Scholar). The tertiary structures of pro- and anti-apoptotic BCL-2 proteins consist of all α-helical protein folds involving one or more conserved BCL-2-homology domains (BH1-4). Although all four BH domains are necessary for the proper functioning of BCL-2 and BCL-XL, the BH3 domains of pro-apoptotic members are themselves sufficient for apoptosis induction (2.Holinger E.P. Chittenden T. Lutz R.J. J. Biol. Chem. 1999; 274: 13298-13304Abstract Full Text Full Text PDF PubMed Scopus (247) Google Scholar). BH3 domains from pro-apoptotic BH proteins also make heterodimer contacts with related anti-apoptotic partners. The structure of the complex of a soluble BCL-XL protein (BCL-XLΔC) and BAK BH3 peptide from nuclear magnetic resonance (NMR) spectroscopy showed peptide bound to a hydrophobic groove bounded by the BH1, BH2, and BH3 domains of BCL-XL (3.Sattler M. Liang H. Nettesheim D. Meadows R.P. Harlan J.E. Eberstadt M. Yoon H.S. Shuker S.B. Chang B.S. Minn A.J. Thompson C.B. Science. 1997; 275: 983-986Crossref PubMed Scopus (1291) Google Scholar). In addition to their ability to nullify pro-apoptotic binding partners, the anti-apoptotic BCL-2 family members may maintain cell survival through regulation of ion and metabolite gradients across mitochondrial membranes. BCL-XL and BCL-2 form pores in synthetic lipid vesicles and membranes. Interestingly, this intrinsic pore-forming activity is inhibited by a bound BAK BH3 peptide (4.Tzung S.P. Kim K.M. Basanez G. Giedt C.D. Simon J. Zimmerberg J. Zhang K.Y Hockenbery D.M. Nat. Cell Biol. 2001; 3: 183-191Crossref PubMed Scopus (439) Google Scholar). It remains an unresolved question whether BCL-XL and BCL-2 affect OMM permeability directly or through interactions with other known mitochondrial channels. For example, BCL-XL may promote osmotic homeostasis by maintaining the voltage-dependent anion channel in an open state, allowing transit of metabolites across the OMM (5.Van der Heiden M. Chandel N.S. Schumacker P.T. Thompson C.B. Molec. Cell. 1999; 3: 159-167Abstract Full Text Full Text PDF PubMed Scopus (452) Google Scholar, 6.Van der Heiden M. Chandel N.S. Li X.X. Schumacker P.T. Colombini M. Thompson C.B. Proc. Natl. Acad. Sci. U. S. A. 2000; 97: 4666-4671Crossref PubMed Scopus (380) Google Scholar, 7.Van der Heiden M. Li X.X. Gottleib E. Hill R.B. Thompson C.B. Colombini M. J. Biol. Chem. 2001; 276: 19414-19419Abstract Full Text Full Text PDF PubMed Scopus (328) Google Scholar). BCL-XL also interacts with the adenine nucleotide translocator, the most abundant protein in the inner mitochondrial membrane and a major component of the permeability transition pore complex (8.Brenner C. Cadiou H. Vieira H.L. Zamzami N. Marzo I. Xie Z. Leber B. Andrews D. Duclohier H. Reed J.C. Kroemer G. Oncogene. 2000; 19: 329-336Crossref PubMed Scopus (309) Google Scholar). Previously, we reported that AA, an inhibitor of mitochondrial electron transport at complex III, selectively kills murine hepatocyte cell lines that over-express BCL-XL or BCL-2 (4.Tzung S.P. Kim K.M. Basanez G. Giedt C.D. Simon J. Zimmerberg J. Zhang K.Y Hockenbery D.M. Nat. Cell Biol. 2001; 3: 183-191Crossref PubMed Scopus (439) Google Scholar, 9.Kim K.M. Giedt C.D. Basanez G. O'Neill J.W. Hill J.J. Han Y.H. Tzung S.P. Zimmerberg J. Hockenbery D.M. Zhang K.Y. Biochem. 2001; 40: 4911-4922Crossref PubMed Scopus (84) Google Scholar). Mitochondrial electron transport inhibition is not correlated with differential killing of BCL-XL-expressing cells, as 2-methoxy AA (2-OMeAA) has similar effects despite a 1000-fold reduction in electron transport inhibition. Rather, a direct effect of AA on BCL-XL function(s) was proposed, based on fluorescent binding assays showing stoichiometric interaction of AA and BCL-XL(ΔC). Computational modeling using the BCLXL(ΔC) NMR structure (3.Sattler M. Liang H. Nettesheim D. Meadows R.P. Harlan J.E. Eberstadt M. Yoon H.S. Shuker S.B. Chang B.S. Minn A.J. Thompson C.B. Science. 1997; 275: 983-986Crossref PubMed Scopus (1291) Google Scholar) predicted a binding site for AA along the long axis of the hydrophobic groove (Fig. 1). Finally, dose-dependent inhibition of BCL-XL(ΔC) pores in synthetic liposomes is observed with either AA or 2-OMeAA. To validate BCL-XL as an important target for 2-OMeAA cytotoxicity, we generated a series of mutant BCL-XL proteins with single amino acid substitutions at predicted contact sites for AA. Analysis of cells expressing mutant BCL-XL proteins confirms the specificity of 2-OMeAA as a BCL-XL inhibitor. In addition, these data provide a detailed mapping of the AA/BCL-XL binding interface. Materials—All reagents were purchased from Sigma unless otherwise noted. Antimycin A1 stocks were prepared in dimethylsulphoxide (Me2SO) and concentrations determined using a molar absorption coefficient of 4.79 mm-1cm-1 at 320 nm. Peptide corresponding to the BH3 domain of BAK (72-GQVGRQLAIIGDDINR-87) was synthesized by the Fred Hutchinson Cancer Research Center core facility. Fluorescein isothiocyanate (FITC)-conjugated BAK BH3 peptide was synthesized by American Peptide Company and purified to >95% by high performance liquid chromatography. Molecular weights were confirmed by matrix-assisted laser desorption/ionization mass spectrometry. 2-OMeAA1 was obtained from the National Cancer Institute. Mutagenesis and Plasmid Construction—BclxL mutants were derived from pSFFV-BclxL-WT (4.Tzung S.P. Kim K.M. Basanez G. Giedt C.D. Simon J. Zimmerberg J. Zhang K.Y Hockenbery D.M. Nat. Cell Biol. 2001; 3: 183-191Crossref PubMed Scopus (439) Google Scholar) using the Stratagene QuikChange XL site-directed mutagenesis kit. Briefly, mutagenic primers spanning each target site were used to amplify fragments containing the desired mutations. Residual wild-type template was then removed by digesting with the methylation-dependent endonuclease, DpnI. For recombinant expression, BclxLΔ22 lacking the COOH-terminal membrane anchor sequence was generated by PCR. PCR products were digested with NdeI and XhoI and ligated into pET22b(+) (Novagen). All constructs were confirmed by sequence analysis. Cell Transfection—TAMH cells were transfected by Lipofectin (LipofectAMINE, Invitrogen) as previously described (4.Tzung S.P. Kim K.M. Basanez G. Giedt C.D. Simon J. Zimmerberg J. Zhang K.Y Hockenbery D.M. Nat. Cell Biol. 2001; 3: 183-191Crossref PubMed Scopus (439) Google Scholar). For analysis of BCL-XL expression, 20 μg of cell protein (1% Triton X-100, 5 mm Tris-HCl, pH 8.0, 150 mm NaCl) was separated by 20% SDS-PAGE and transferred (electrophoretic) to nitrocellulose membranes. Immunodetection of BCL-XL was carried out using rabbit anti-BCL-XL antibody and Protein A/horseradish peroxidase conjugate (BD Transduction Laboratories), followed by chemiluminescent detection (Amersham Biosciences). Cell Viability Assays—Cells were grown to ∼80% confluence in 96-well plates followed by addition of 100 μl of 2× AA1 or staurosporine (STS) solution in complete medium. Cell viability was determined spectrophotometrically after 24 h treatment as the ratio of reduced and oxidized Alamar Blue (BIOSOURCE) at 570 and 600 nm, respectively. All results were normalized against Me2SO controls. Similar results were obtained using sulforhodamine B assays for total cell protein (data not shown). LD50 values were calculated by non-linear regression analysis using Prism software (Graphpad). Recombinant BCL-XL Purification—A pET22b (Novagen) vector coding for BCL-XL (ΔC), was transformed into Escherichia coli BL21 (DE3) cells that carried pUBS520 (encoding human Arg tRNA) and grown to an A600 of 0.6. Protein expression was induced with 0.1 mm isopropyl β-d-thiogalactoside at 30 °C. The cells were resuspended 1:5 (w/v) in PEB buffer (50 mm Tris, pH 8.0, 0.2 m NaCl, 0.2 mm phenylmethylsulfonyl fluoride, 5 mm β-ME, 5mm imidazole, and 1% (v/v) glycerol), and stirred for 20 min at 4 °C. Cells were disrupted by pulse sonication, and the soluble fraction was loaded onto a nickel-nitrilotriacetic acid column (Qiagen) equilibrated with PEB buffer. The column was washed with 40 mm imidazole, eluted with 200 mm imidazole, and the protein fractions were pooled and dialyzed (50 mm Tris, pH 8.0, 200 mm NaCl, 1 mm dithiothreitol, 2 mm EDTA, 0.2 mm phenylmethylsulfonyl fluoride) at 4 °C overnight. The dialyzed protein was concentrated to 10 mg/ml and fractionated on a Superdex 75 gel filtration column (Amersham Biosciences). The fractions containing BCL-XL(ΔC) protein were pooled, exchanged into low-salt buffer (same as for previous dialysis buffer, except 50 mm NaCl), and loaded onto a MonoQ anion exchange column (Amersham Biosciences). Protein was eluted from the column with increasing NaCl gradient, pooled, and concentrated. Purity was >99% as determined by silver staining. BCL-XL(ΔC) protein concentrations in 6 m guanidine HCl were determined from 280 nm absorbance using extinction coefficients of 41940 m-1cm-1 for WT, E92L, A142L, and F146L, and 47630 m-1cm-1 for F97W BCL-XL(ΔC) proteins. Fluorescence Anisotropy—Fluorescence anisotropies of AA1 and FITC-labeled BAK BH-3 peptide were measured using a Fluoromax-3 spectrometer equipped with autopolarizers (Jobin Yvon/Spex). All reagents were prepared in 0.2 μm-filtered phosphate-buffered saline with fresh 1 mm dithiothreitol. Excitation and emission wavelengths were 340 and 420 nm for AA1, and 480 and 520 nm for FITC-labeled BAK BH3 peptide, respectively. Slit widths were set at 10 nm for both excitation and emission. AA1 (200 nm) or BH3 peptide (25 nm) were equilibrated with different concentrations of BCL-XL(ΔC) for at least 1 h at room temperature. Each data point represents the mean of three independent measurements. Fluorescence anisotropy values were converted to fraction of ligand bound (fB) and expressed on a semi-log plot with non-linear curve fitting (10.Lakowicz J.R. Principles of Fluorescence Spectroscopy. 2nd Ed. Kluwer Academic/Plenum Publishers, New York1999: 308-309Google Scholar). Membrane Pore Assays—Large unilamellar vesicles composed of 60% dioleoyl phophatidylcholine and 40% dioleoyl phosphatidylglycerol were prepared by the extrusion method of Mayer et al. (11.Mayer L.D. Hope M.J. Cullis P.R. Biochim. PubMed Scopus Google Scholar). in were and a of The lipid was resuspended by for 30 min in a solution of 40 mm mm and 10 mm pH 10 the lipid was through 0.1 pore was removed by a column (Amersham Biosciences). was measured using the method J.C. Biochem. PubMed Scopus Google Scholar). For pore recombinant BCL-XL(ΔC) nm) was to unilamellar vesicles lipid in 100 mm 10 mm pH and measured nm 520 nm with a Fluoromax-3 Peptide was with BCL-XL(ΔC) 5 min to with AA was to liposomes 1 min BCL-XL(ΔC) for assays were in a at °C with were measured in at room temperature. was expressed as of with Triton Pore inhibition was calculated using normalized to results obtained in of and the values were determined by non-linear regression analysis. and mutant BCL-XL(ΔC) proteins were concentrated to 1 mm and by at 4 °C. The of 50 mm pH m were in liquid after in for 1 were at 100 with a and 50 and a and Z. J. Scholar) were used to the The Biol. D. 1999; PubMed Scopus Google Scholar) was used to a solution using the structure as a The for and all mutant proteins was determined to A set PubMed Scopus Google Scholar) of was set using the The from the J. Biol. 1999; PubMed Scopus Google Scholar) was used to and the The J. M. N.S. R.J. T. Biol. D. PubMed Scopus Google Scholar) was used for and were used to The of all structures were by J. Google Scholar). and were with N. 1997; 18: PubMed Scopus Google with using previously described in Tzung et al. (4.Tzung S.P. Kim K.M. Basanez G. Giedt C.D. Simon J. Zimmerberg J. Zhang K.Y Hockenbery D.M. Nat. Cell Biol. 2001; 3: 183-191Crossref PubMed Scopus (439) Google the NMR structure of the BAK BH3 of BCL-XL was used as a target for AA1 binding. The binding was used to contacts AA1 and BCL-XL proteins were on using and the of the was using The binding of AA1 was into the root mean square and were calculated using the of contacts is based on and J. of Protein and J. of Protein and based on the in a contact or The for BCL-XL mutants is based on at the BCL-XL to series of point were to in the BCL-XL hydrophobic groove contact with AA from the The single amino acid substitutions were in human E92L, A142L, and obtained of murine for each of the as as wild-type BCL-XL and wild-type proteins were expressed at similar levels (Fig. To the effect of on BCL-XL we cells for survival that each of the proteins levels of against cell LD50 values for with cells expressing were not different from cells 0.1 (Fig. and cells expressed levels of BCL-XL and were more to of the or cell lines (Fig. of AA1 activity on and mutant BCL-XL proteins mutant and wild-type values as determined by analysis of that the non-linear regression was to this curve to a of BH3 10 10 in a and cells with In to the results with STS, AA sensitivity the cell with cells 0.1 the and F97W cells reduced sensitivity to AA and the and cells were to AA (Fig. and BCL-XL for and wild-type proteins were purified from by nickel-nitrilotriacetic acid gel and column chromatography. of AA1 binding to BCL-XL(ΔC) proteins were obtained from anisotropy constants were calculated using non-linear regression analysis AA1 has binding with the A142L, and mutants and with protein (Fig. The binding of AA1 with the mutant is reduced to the of in vitro AA1 binding for the proteins is in with the in to AA. The BCL-XL and with and in the BCL-XL hydrophobic by NMR A. A. M. B. G. T. J. Nat. Cell Biol. 2001; 3: PubMed Scopus Google Scholar, J. G. J. Chem. PubMed Scopus Google Scholar). determined that with AA1 for BCL-XL binding (Fig. The for of AA bound to BCL-XL is similar to that reported for BH3 peptide by et al. A. A. M. B. G. T. J. Nat. Cell Biol. 2001; 3: PubMed Scopus Google Scholar). also determined the effects of the hydrophobic groove on binding of BAK BH3 domain Fluorescence anisotropy were using a FITC-labeled BAK The A142L, and in BH3 peptide binding with (Fig. and Interestingly, the of BAK BH3 peptide with the BCL-XL(ΔC) proteins F97W determined for AA. of BCL-XL lipid vesicles were loaded with the fluorescent to membrane pore by recombinant BCL-XL(ΔC) proteins. of AA1, or the BAK BH3 peptide inhibited BCL-XL a antimycin a a BAK peptide with BCL-XL and effect (Fig. The mutant of BCL-XL(ΔC) similar pore-forming as (Fig. the sensitivity of pores to AA1 and to BAK BH3 peptide similar (Fig. and and non-linear regression analysis of the to values Although the of AA1 values in the is observed for the binding of AA1 using soluble the of is F97W The BAK BH3 peptide values also the observed for the binding obtained from the binding of with BCL-XL structures of and the four proteins, E92L, A142L, and F146L, were by the effects on the 5 an of with the mutant The of the BCL-XL mutants from to the the of contacts the of AA1, the the hydrophobic groove with ligand The structure of BCL-XL(ΔC) at with and a the and The and are interactions the BH3 α-helical domain and the COOH-terminal of BCL-XL(ΔC). the structure is similar to WT, with a of and an of in to the of AA1 in the the of a in this is to a with bound The structure of F97W BCLXL(ΔC) was to The F97W not the structure of F97W of to for the The for F97W BCL-XL(ΔC) in this with through an of this is in the structure of a peptide complex the effects of on AA1 is to in the hydrophobic The for AA1 predicts a the of AA1 and the The structure of BCL-XL(ΔC) was to The BCL-XL(ΔC) structure is similar to with a of The a of of the and of the of and from positive to negative (Fig. the of the the is conserved with and also negative in the BH3 the binding in the of BCL-XL(ΔC) the other BCL-XL the predicts a of der contacts to the of AA1 with the The BCL-XL structure was to The structure an of is of the with The and of the and to wild-type with the of the of with the BCL-XL(ΔC) and from positive to negative In addition, the has a positive in BCL-XL (Fig. the across all for in the are that of the of the the in at in the proteins may an of this The BCL-XL structure also of an by may the of the protein E. J. J. Biol. PubMed Scopus Google Scholar, J. E. Sci. PubMed Scopus Google Scholar). In this has a calculated of to in the mutant (4.Tzung S.P. Kim K.M. Basanez G. Giedt C.D. Simon J. Zimmerberg J. Zhang K.Y Hockenbery D.M. Nat. Cell Biol. 2001; 3: 183-191Crossref PubMed Scopus (439) Google Scholar, 9.Kim K.M. Giedt C.D. Basanez G. O'Neill J.W. Hill J.J. Han Y.H. Tzung S.P. Zimmerberg J. Hockenbery D.M. Zhang K.Y. Biochem. 2001; 40: 4911-4922Crossref PubMed Scopus (84) Google Scholar) that expression of the anti-apoptotic protein BCL-XL cells to AA. AA directly to BCL-XL(ΔC) in with BH3 peptide that the hydrophobic with the of this interface as the AA binding site by In this we used site-directed mutagenesis to validate BCL-XL as a direct target for AA and the BCL-XL binding site for AA in out of four in the BCL-XL hydrophobic groove A142L, and or the ability of BCL-XL to cell to AA1 Each of the mutants wild-type activity with staurosporine of protein function as an for the to we reduced binding of AA1 with the proteins, with a binding and in sensitivity to The BCL-XL were for on The structures of the BCLXL(ΔC) mutants of the tertiary protein allowing of the binding data in of the for AA1 the structure of BCL-XL(ΔC) bound to BAK BH3 with the and BCL-XL is of the predicted to AA1 contacts in these structures for and (Fig. The AA1 binding of the proteins are as F97W these single into the AA1 to their effects on AA1 binding. F97W and are to to the In the the of the contacts to the of AA1 (Fig. the a to the AA1 (Fig. The and in the of AA1 binding for F97W and with are with these To form a of the BCL-XL binding or AA1 from the The at is to the of AA1 in the (Fig. predicted interaction of der contacts and interactions the negative of the and positive of the of for both of contacts with AA, for the in AA1 with this mutant the structure based on the structures provide for the measured AA1 binding The was not to AA binding based on the as is at the of the binding and a contact with the reduction of AA1 binding with the an of the effects on binding for at The reduction in may to of the BCL-XL tertiary structure by the of The anti-apoptotic of BCL-XL and BCL-2 through and are by with pro-apoptotic proteins. The proteins normal anti-apoptotic activity despite binding to the pro-apoptotic BH3 BCL-XL binding for BH3 on hydrophobic interactions at the of the with conserved and in the studies of the BAK BH3 peptide to the BCL-XL mutants that the interactions with BAK the F97W to to a with the of BAK BCL-XL a to a the of BAK and the BCL-XL these results that the mutant are more with the pro-apoptotic binding negative the anti-apoptotic function of BCL-XL, we a single pro-apoptotic BH3 domain For example, BCL-XL and BCL-2 proteins with binding to BAK with the BH3 protein in a previous S. Chang J. G. Chang S. S. T. J. Biol. Chem. 1997; Full Text Full Text PDF PubMed Scopus Google Scholar). The hydrophobic groove not affect the ability of purified BCL-XL(ΔC) in synthetic that this is by the protein and of BCL-XL(ΔC). AA1 inhibited pore of mutant and wild-type proteins with similar The of this for mutants with different AA binding AA1 interacts with soluble lipid in resonance we determined that AA1 not with the of BCL-XL into lipid BAK BH3 membrane of the of BAK BH3 values for the BCL-XL mutant series the of for soluble BCL-XL pore inhibition at a The conserved of mutant protein in AA binding and pore assays F97W for in the soluble and binding The interaction in a lipid to by the BCL-XL with the soluble form of the previous that AA selectively kills BCL-XL-expressing cells by directly BCL-XL is by the studies reported The single amino acid in the binding allowing a high of in from structures to the protein The principal for the AA of the mutant BCL-XL proteins to binding as by the in vitro binding constants and cytotoxicity. In these results with the of AA1 to the BCL-XL hydrophobic in this BCL-XL inhibitor and of the at the Fred Hutchinson Cancer Research Center for their with
23